Catalyst Brief

← Calendar

Readoutin 76d

Gilead Sciences — Sacituzumab Govitecan-hziy

Phase 3 primary completion: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer.

Date
Feb 2027
Type
Readout
Indication
Triple Negative Breast Cancer

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.